BOSTON--(BUSINESS WIRE)--Atalanta Therapeutics, a biotechnology company pioneering new treatment options for neurodegenerative diseases, launched today with a Series A financing exclusively by F-Prime ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Blackstone (NYSE: BX) and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the closing of the R&D funding ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the planned expansion of its state-of-the-art manufacturing facility in Norton, Massachusetts. The ...

Please provide your email address to receive an email when new articles are posted on . RNA therapeutics lowered all-cause mortality, increased 6-minute walk distance and improved quality of life. RNA ...

– Qfitlia Becomes the Sixth Alnylam-Discovered RNAi Therapeutic Approved by U.S. FDA and First and Only to Treat Hemophilia A or B With or Without Inhibitors – Qfitlia is the sixth Alnylam-discovered ...

During an oral Spotlight Presentation, Codexis unveiled the successful end-to-end enzymatic synthesis of an entire approved siRNA therapeutic asset, inclisiran. Codexis enzymatically synthesized the ...

− Presents Pre-clinical Data with IKARIA Platform Demonstrating Potential to Achieve Over 90% Target Knockdown with an Annual Dosing Regimen – “At OTS this year we are pleased to share research ...

Partnership focuses on discovery of cationic lipids and lipid nanoparticles. Alnylam Pharmaceuticals and Tekmira Pharmaceuticals are collaborating to discover cationic lipids and lipid nanoparticles ...

(MENAFN- EIN Presswire) EINPresswire/ -- "What Is The Expected Cagr For The Antisense & RNAi Therapeutics Market Through 2025? In the past few years, there has been a substantial increase in the size ...

Alnylam, based in Cambridge, Mass., exposed 88 male volunteers to respiratory syncytial virus, which affects mostly young children and the elderly. Half of the subjects received the RNAi treatment, ...

With demand for its RNA interference meds booming, Alnylam Pharmaceuticals has commenced work to soup up its flagship ...